Epithelial ovarian cancer: Difference between revisions

Revision as of 15:51, 26 February 2019

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Hannan Javed, M.D.[2]


Possible genetic alteration in epithelial ovarian cancers
Protein	Normal function	Result of mutation
Epidermal growth factor receptor (HER-1)^[1]^[2]	Promotes cell proliferation Opposes apoptosis Regulates differentiation	Activating mutation Increased cellular proliferation Inhibition of apoptosis
Human Epidermal Growth Factor Receptor 2 (HER-2)^[1]^[2]	Promotes cell prolifeartion Inhibition of apoptosis Regulates differentiation	Activating mutation Increased cellular proliferation Inhibition of apoptosis
Non-receptor tyrosine kinase Src^[3]^[4]	Involved in regulation of Gene transcription Angiogenesis Cellular adhesion Cellular proliferation	Activating mutation Increased angiogenesis Decreased cellular adhesion Increased tumor metastasis Increased cellular proliferation
CSF-1/fms^[5]	Increased macrophage survival Increased macrophage proliferation Increased macrophage differentiation	Activating mutation Stimulation of tumor cell proliferation Increased angiogenesis Promotes tumor invasion Increased metastasis Decreased anoikis
ILGF/ILGFR
k-ras
b-raf
TGF-β
myc
Cyclin D/Cdk4/6
Cyclin E/Cdk2
Cyclin B/Cdk1
p16
p27 (kip-1)
p21 (WAF-1)
NFκB
NOEY(ARHI)
PIP3/Akt
PTEN
p53
BRCA1
BRCA2
MLH1/MSH2
Fas ligand
HLA-G
hTERT
VEGF/VEGFR
IL-8
EphA2
MMPs
αvβ3
FAK
E-cadherin

↑ ^1.0 ^1.1 Wee P, Wang Z (May 2017). "Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways". Cancers (Basel). 9 (5). doi:10.3390/cancers9050052. PMC 5447962. PMID 28513565.
↑ ^2.0 ^2.1 Iqbal N, Iqbal N (2014). "Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications". Mol Biol Int. 2014: 852748. doi:10.1155/2014/852748. PMC 4170925. PMID 25276427.
↑ Zan L, Wu H, Jiang J, Zhao S, Song Y, Teng G, Li H, Jia Y, Zhou M, Zhang X, Qi J, Wang J (July 2011). "Temporal profile of Src, SSeCKS, and angiogenic factors after focal cerebral ischemia: correlations with angiogenesis and cerebral edema". Neurochem. Int. 58 (8): 872–9. doi:10.1016/j.neuint.2011.02.014. PMC 3100427. PMID 21334414.
↑ Reinecke JB, Katafiasz D, Naslavsky N, Caplan S (April 2014). "Regulation of Src trafficking and activation by the endocytic regulatory proteins MICAL-L1 and EHD1". J. Cell. Sci. 127 (Pt 8): 1684–98. doi:10.1242/jcs.133892. PMC 3986674. PMID 24481818.
↑ Dwyer AR, Greenland EL, Pixley FJ (June 2017). "Promotion of Tumor Invasion by Tumor-Associated Macrophages: The Role of CSF-1-Activated Phosphatidylinositol 3 Kinase and Src Family Kinase Motility Signaling". Cancers (Basel). 9 (6). doi:10.3390/cancers9060068. PMC 5483887. PMID 28629162.

@@ Line 44: / Line 44: @@
 * Increased cellular proliferation
 |-
-|CSF-1/fms
+|CSF-1/fms<ref name="pmid28629162">{{cite journal |vauthors=Dwyer AR, Greenland EL, Pixley FJ |title=Promotion of Tumor Invasion by Tumor-Associated Macrophages: The Role of CSF-1-Activated Phosphatidylinositol 3 Kinase and Src Family Kinase Motility Signaling |journal=Cancers (Basel) |volume=9 |issue=6 |pages= |date=June 2017 |pmid=28629162 |pmc=5483887 |doi=10.3390/cancers9060068 |url=}}</ref>
 |
 * Increased macrophage survival